KRS Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,739
Closed -$267K 114
2023
Q1
$267K Sell
1,739
-90
-5% -$14.8K 0.3% 90
2022
Q4
$329K Buy
+1,829
New +$299K 0.45% 76
2022
Q1
Sell
-775
Closed -$196K 256
2021
Q4
$196K Buy
+775
New +$227K 0.17% 121

Other funds holding MRNA

KRS Capital Management's MRNA Position: Q2 2023 in Review

KRS Capital Management sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,739 shares — an estimated $267K sold.

KRS Capital Management first reported a position in MRNA in Q4 2021 and held it in 3 quarters. The position peaked at $329K in Q4 2022. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • KRS Capital Management reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • KRS Capital Management sold 1,739 Moderna shares in Q2 2023, an estimated $267K.
  • KRS Capital Management first reported a position in Moderna in Q4 2021 and held it in 3 quarters.
  • KRS Capital Management's Moderna position peaked at $329K in Q4 2022.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on KRS Capital Management's 13F filing for Q2 2023, filed 14 Jul 2023.